

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Brioni, *et al.*

Serial No.: 09/985,974

Filed: November 7, 2001

Title: THE USE OF SELECTIVE
DOPAMINE BY RECEPTOR AGONISTS
FOR TREATING SEXUAL
DYSFUNCTION

Case No.: 6753.US.02

Group Art No.: 1617

Examiner: Bahar, Mojdeh

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Box DAC
Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: April 21, 2003

Tanya Parent Date

Box DAC
Commissioner for Patents
Washington, D.C. 20231

RESPONSE AND REQUEST FOR RECONSIDERATION

Dear Sir:

This communication is responsive to the Office Action dated September 10, 2002 and is accompanied by a Petition To Revive An Unintentionally Abandoned Application under 37 C.F.R. §1.137 (b).

Claims 1-30 are pending.

Claims 1, 5, 15-22, 26, 2, 4, 6, 8, 9, 11, 12, 14, 23, 25, 27 and 29 stand rejected.

Applicants reserve the right to file divisional applications on all non-elected subject matter of the instant application.

The Applicants mistakenly elected claims 16 and 39 in the August 8, 2002 Response, where claims 14 and 29 should have been elected.

Claims 1, 5, 22 and 26 (all in part), 2, 4, 6, 8, 9, 11, 12, 14, 23, 25, 27 and 29 stand rejected under 35 USC 103(a) as unpatentable over Glase *et al.* and Zorn *et al.* in view of US 5,714,487 to Sanner. Sanner does not teach or suggest the use of D4 ligands for the treatment of sexual dysfunction. The Glase reference describes a D4 selective agonist and states that it may provide a useful tool in determining the contribution of D4 receptors to schizophrenia. Zorn merely discloses CP226269 as a selective D4 agonist. Applicants respectfully submit that the cited references do not teach or suggest the use of D4 agonist for treating sexual dysfunction.


Accordingly, Applicants respectfully request allowance of the claims.



23492

ABBOTT LABORATORIES
Telephone: (847) 938-3490
Facsimile: (847) 938-2623

Respectfully submitted,
Brioni, *et al.*


Michael J. Ward
Registration No. 37,960
Attorney for Applicants

RECEIVED

APR 30 2003

OFFICE OF PETITIONS